" class="no-js "lang="en-US"> Barry Canton - Medtech Alert
Monday, May 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Barry Canton

Barry Canton

About Barry Canton

Related Story

Industry News

 Ginkgo Bioworks Acquires Bitome

Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform

June 7 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has […]

Drug Development

 Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines Using Synthetic Biology | Pharmtech Focus

Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines Using Synthetic Biology

August 13 2021

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the […]